Most Likely Diagnosis: Type 1 Diabetes Mellitus (B)
This patient has Type 1 diabetes mellitus, evidenced by the critically low C-peptide level (0.09 ng/mL) indicating absolute insulin deficiency, despite a previous diagnosis of type 2 diabetes. The polyuria and polydipsia with an HbA1c of 8% reflect inadequate glycemic control from progressive β-cell failure.
Diagnostic Reasoning
Why Type 1 Diabetes is Correct
The C-peptide level of 0.09 ng/mL is profoundly low and represents the most critical finding. According to AACE/ACE guidelines, type 1 diabetes is characterized by absolute insulin deficiency confirmed by low C-peptide levels 1. The 2025 ADA guidelines specify that C-peptide values <200 pmol/L (<0.6 ng/mL) indicate type 1 diabetes, and this patient's value of 0.09 ng/mL falls well below this threshold 2.
This represents latent autoimmune diabetes in adults (LADA) or a delayed presentation of type 1 diabetes initially misclassified as type 2. The guidelines explicitly state that documenting C-peptide levels helps distinguish between T1D and T2D in adults and that type 1 diabetes can occur in people who are overweight or obese 1. The family history of type 1 diabetes further supports this diagnosis 1.
Why Other Options are Incorrect
Diabetes Insipidus (A): The normal urine and serum osmolality definitively exclude this diagnosis. Diabetes insipidus presents with dilute urine (low osmolality) and elevated serum osmolality, neither of which are present here.
Type 2 Diabetes Mellitus (C): While the patient carries this diagnosis, type 2 diabetes is characterized by insulin resistance with elevated fasting insulin and/or C-peptide concentrations 1. This patient's C-peptide is severely suppressed, not elevated, indicating absolute insulin deficiency incompatible with type 2 diabetes.
Hyperparathyroidism (D): Although the PTH is elevated with normal calcium (suggesting normocalcemic primary hyperparathyroidism), this does not explain the diabetes symptoms. The French consensus guidelines indicate that primary hyperparathyroidism can present with polyuria-polydipsia syndrome 3, but this is due to hypercalcemia-induced nephrogenic effects, not from hyperglycemia. The normal calcium excludes typical hyperparathyroidism as the primary cause of symptoms.
Critical Clinical Pitfall
The elevated PTH with normal calcium represents secondary hyperparathyroidism from vitamin D supplementation history. The guidelines emphasize that vitamin D deficiency is a frequent cause of secondary hyperparathyroidism and that vitamin D status must be normalized for >6 months before diagnosing primary hyperparathyroidism 3. Recent research shows that chronic hyperglycemia (HbA1c ≥10%) is associated with attenuated PTH responsiveness 4, and PTH is negatively correlated with HbA1c in type 2 diabetic patients 5. This patient's PTH elevation is likely reactive to previous vitamin D deficiency, not primary parathyroid disease.
Management Implications
This patient requires immediate insulin therapy. The profoundly low C-peptide indicates no meaningful endogenous insulin production. Continuing oral agents alone would be inappropriate and dangerous. The polyuria and polydipsia with HbA1c of 8% indicate symptomatic hyperglycemia requiring urgent intervention.
Consider checking:
- Islet autoantibodies (GAD, IA-2, ZnT8) to confirm autoimmune type 1 diabetes 1, 2
- Repeat vitamin D levels to assess supplementation adequacy
- Reassess PTH after 6+ months of vitamin D normalization 3
The normal osmolality values confirm the polyuria is osmotic (from glucosuria) rather than from diabetes insipidus or hypercalcemia.